¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇѽɺÎÀüÇÐȸ Á¦43Â÷ Ãß°è Çмú´ëȸ(Heart Failure Seoul 2021) 3ÀÏÂ÷ : 2021-09-18

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

´ëÇѽɺÎÀüÇÐȸ Á¦43Â÷ Ãß°è Çмú´ëȸ(Heart Failure Seoul 2021) 3ÀÏÂ÷ : 2021-09-18
±³À°ÀÏÀÚ : 2021-09-18
±³À°Àå¼Ò : ±×·£µå ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï Æĸ£³ª½º 5Ãþ ±×·£µåº¼·ë  
±³À°ÁÖÁ¦ : ´ëÇѽɺÎÀüÇÐȸ Á¦43Â÷ Ãß°è Çмú´ëȸ(Heart Failure Seoul 2021) 3ÀÏÂ÷
ÁÖÃÖ±â°ü : ´ëÇѽÉÀåÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѽɺÎÀüÇÐȸ  
´ã´çÀÚ : ¹éÁöÀº
¿¬¶ôó : 02-3275-5335  
À̸ÞÀÏ : kshf4@kshf.or.kr      
±³À°Á¾·ù : ³»°ú      
Âü¼®¿¹»óÀοø : 400¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 70,000¿ø      
ºñ°í ±³¼ö: 70,000¿ø, ÀϹÝÀÇ: 30,000¿ø, Àü°øÀÇ, °£È£»ç, 65¼¼ ÀÌ»ó, Çлý, ±âŸ(ÀÌ¿Ü ÀÇ·áÁ¾»çÀÚ): ¹«·á      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 10:00~10:30 Optimal HFrEF Treatment, New Perspectives  James Januzzi(Harvard University USA) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 10:30~11:00 Role of SGLT2I from Chronic to Acute HF, Where Is Proper Position in GDMT?  Michael Bohm(Saarland University Germany) 
Åä·Ð 09-18 ±×·£µåº¼·ë 11:00~11:20 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
È޽Ġ09-18 ±×·£µåº¼·ë 11:20~11:30 Break Time  () 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 11:30~11:45 Smartphone Application for Cardiac Rehabilitation: Strength and Weakness  ±èÀÀÁÖ(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 11:45~12:00 Skeletal Muscle and Prognosis of HF: Can Cardiac Rehabilitation Overcome Muscle Wasting?  Kazunori Shimada(Juntendo University Hospital Japan) 
Åä·Ð 09-18 ±×·£µåº¼·ë 12:00~12:10 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
½Ä»ç 09-18 ±×·£µåº¼·ë 12:10~13:00 Lunch  () 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 13:00~13:50 Brigntening Abstract Presentation (II)  () 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 13:50~14:10 Challenge of Prescribing Inertia: from CHAMP-HF Registry  Biykem Bozkurt(Baylor College of Medicine HoustonTX) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 14:10~14:25 Performance Measures for HF Management in Korea  À±Á¾Âù(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 14:25~14:45 Benefits of Quadruple Therapy for HFrEF  JoAnn Lindenfeld(Vanderbilt University Medical Center Nashville TN) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 14:45~15:00 Comprehensive or Stepwise Treatment for HFrEF  ÃÖÁ¤Çö(ºÎ»êÀÇ´ë) 
Åä·Ð 09-18 ±×·£µåº¼·ë 15:00~15:20 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
È޽Ġ09-18 ±×·£µåº¼·ë 15:20~15:30 Break Time  () 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 15:20~15:35 Benefit of SGLT2 Inhibitors across the Cardiorenal Continuum  ±ÇÇõ»ó(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 15:35~15:50 Mechanistic Background of the Benefit of SGLT2 Inhibitors: Non-cardiac effect  ÃÖ¼ºÈñ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 15:50~16:05 Mechanistic Background of the Benefit of SGLT2 Inhibitors: Cardiac Effect  Á¶Àͼº(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 16:05~16:20 Positioning of SGLT2 Inhibitors in HF Management: How Should We Sequence?  John McMurray(Univ of Glasgow. UK) 
Åä·Ð 09-18 ±×·£µåº¼·ë 16:20~16:50 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó) 
È޽Ġ09-18 ±×·£µåº¼·ë 16:50~17:00 Break Time  () 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 17:00~17:15 Ischemic Cardiomyopathy  Yuhui Zhang(CHFA China) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 17:15~17:30 Idiopathic Dilated Cardiomyopathy  ÀÌ»ó¾ð(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 17:30~17:45 Acute and Chronic Myocarditis  Jian Zhang(CHFA China) 
±³À°½Ã°£ 09-18 ±×·£µåº¼·ë 17:45~18:00 Hypertrophic Cardiomyopathy  ±èÀÎö(°è¸íÀÇ´ë) 
Åä·Ð 09-18 ±×·£µåº¼·ë 18:00~18:30 Discussion  ´Ù°­»ç(´Ù¼Ò¼Ó)  

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇѽɺÎÀüÇÐȸ Á¦43Â÷ Ãß°è Çмú´ëȸ(Heart Failure Seoul 2021) 3ÀÏÂ÷ : 2021-09-18""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ (¿Â¶óÀÎ) Á¦58Â÷ ¾Ë·¹¸£±â ±³À°°­Á : 2021-09-25
´ÙÀ½±Û ´ëÇѽɺÎÀüÇÐȸ Á¦43Â÷ Ãß°è Çмú´ëȸ(Heart Failure Seoul 2021) 2ÀÏÂ÷ : 2021-09-17
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20439 ¼­¿ï ´ëÇÑÃÊÀ½ÆÄÀÇÇÐȸ AFSUMB 2024_ Day3 : 2024-05-11 0 33 2024-04-17
20438 ¼­¿ï ´ëÇÑÅëÁõÀÚÀ²½Å°æÇÐȸ 2024 ÀÓ»ó½Å°æ»ý¸® ¿¬ÇÕ°­Á : 2024-05-11 0 38 2024-04-17
20437 ¼­¿ï 2024³âµµ ´ëÇѼҾÆû¼Ò³âÁ¤½ÅÀÇÇÐȸ 40ÁÖ³â Ãá°èÇмú´ëȸ : 2024-05-10 0 39 2024-04-17
20436 Àü³² 2024³â ´ëÇѹæ»ç¼±Á¾¾çÇÐȸ Ãá°èÇмú´ëȸ : 2024-05-10 0 37 2024-04-17
20435 ´ë±¸ 2024³â ´ëÇÑ°í°üÀýÇÐȸ ±¹Á¦Çмú´ëȸ(ICKHS 2024) (2ÀÏÂ÷) : 2024-05-10 0 58 2024-04-16
20434 ¼­¿ï ´ëÇÑÃÊÀ½ÆÄÀÇÇÐȸ AFSUMB 2024_ Day2 : 2024-05-10 0 41 2024-04-16
20433 ´ë±¸ 2024³â ´ëÇÑ°í°üÀýÇÐȸ ±¹Á¦Çмú´ëȸ(ICKHS 2024) (1ÀÏÂ÷) : 2024-05-09 0 61 2024-04-16
20432 ¼­¿ï ´ëÇÑÃÊÀ½ÆÄÀÇÇÐȸ AFSUMB 2024_Day1 : 2024-05-09 0 43 2024-04-16
20431 ÀüºÏ ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ ÀüºÏÁöºÎ 5¿ù ÇмúÁý´ãȸ : 2024-05-07 0 28 2024-04-16
20430 Ãæ³² ¼øõÇâ´ëÇб³Ãµ¾Èº´¿ø ½Å»ý¾Æ ¼Ò»ý¼ú ¿¬¼ö°­Á : 2024-05-03 0 47 2024-04-16
20429 ¼­¿ï °­³²¼¼ºê¶õ½ºº´¿ø (¿Â¶óÀÎ) ¼Ò¾Æû¼Ò³â°ú Çù·ÂÀÇ»ç Áý´ãȸ : 2024-04-30 0 63 2024-04-16
20428 ¼­¿ï (¿Â¶óÀÎ) ¸¸¼ºÁúȯ Ä¡·á(Chronic Disease Care)¿¬¼ö±³À° : 2024-04-30 0 82 2024-04-16
20427 °æ±â ÀÌõ½ÃÀÇ»çȸ ¿¬¼ö°­Á : 2024-04-29 0 26 2024-04-16
20426 ´ëÀü ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ 2024³âµµ 4¿ù ´ëÀüÃæ³²ÁöºÎÇÐȸ ¿ù·ÊÁý´ãȸ : 2024-04-29 0 46 2024-04-16
20425 ºÎ»ê ºÎ»ê´ëÇб³º´¿ø ÇǺΰúÇÐÀÇ ÃÖ½ÅÁö°ß : 2024-04-29 0 51 2024-04-16
11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷